High performance and widely accessible secretomics assay platform

Ended Project Grant Awarded Last action

Award ID
R44GM148138
Recipient
Awarding agency
Obligated
$1,730,105

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date
Place of performance
Missouri, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Secretory proteins are fundamental to local and systemic cellular signaling in biological systems. The regulation and dysregulation of the networks involving these proteins plays a critical role in health, aging, and development of disease. As such, study of these proteins and their networks is critical to our understanding of biology. Not surprisingly, this particular set of proteins constitutes a large proportion of the targets of pharmaceutical drugs, and also represents attractive targets for diagnostics and future precision medicine efforts. Unfortunately, many of these secreted proteins are difficult to detect. There are existing technologies for studying these secreted proteins but they either underperform, are extremely expensive and/or complex given their specific-utility. Containing multiple cell types. Although the need to study secreted proteins is ubiquitous, there is not a technology that is widely available (INEXPENSIVE) and capable of providing information on multiple secreted proteins simultaneously at single-cell resolution, and we aim to address this need in the current project. At the core of our technologies is the plasmonic fluor (PF), our proprietary, ultrabright fluorescent nanoconstruct designed to enhance the performance of fluorescence-based immunoassays. We have already built a high-sensitivity, multiplexed immunoassay platform leveraging this technology, which is currently being tested with external collaborators. This platform includes an INEXPENSIVE, high performance, single-laser fluorescence microplate/slide reader optimized for use with our PFS. We will extend this existing platform to accommodate PF- enhanced cellular secretion assays we call pfluorospot. The upgraded platform that will result from the proposed effort will be a truly versatile and powerful tool for the measurement of proteins. In our preliminary work, we have successfully manufactured at commercial scale and with high reproducibility streptavidin-conjugated PFS that are spectrally equivalent to fitc, CY3, and CY5 (PF490, PF550, and PF650, respectively). We have also created three PFS with entirely unique excitation/emission spectra: two which have excitation spectra like fitc and emit like CY3 and CY5 (PF490_550 and PF490_650, respectively), and one which has an excitation spectrum like CY3 but emits like CY5 (PF550_650). These unique PFS were synthesized at a prototype scale which we aim to scale up in this effort because they will allow 3 lasers to be used to interrogate 6 separate targets. In a demonstration of applicability to cellular secretion assays, streptavidin-PF550 and PF650 were conjugated to antibodies at a small scale and used to perform dual-color pfluorospot. These initial pfluorospot experiments show that additional information can be obtained in these assays relative to elispot/fluorospot, and are simpler and significantly faster to perform. IT was possible to visualize individual cells for adherent cells and better localize secreting cells. This is particularly important for understanding heterogeneity, spatial effects in CO-culture, and polyfunctionality, and we propose to add a 4TH laser to our reader to accommodate cell markers. Additionally, a single-color pfluorospot assay was read with our existing reader and demonstrated high sensitivity, high resolution, and short read times. We believe our pfluorospot platform and reader will become the go-to secretomics platform, and will empower many more biological researchers to measure important, secreted proteins.

Transactions

Action Obligated Date
Amendment $0
Amendment $786,574
Original award $943,531

Quick answers

Who received award R44GM148138?

R44GM148138 was awarded to Auragent Bioscience LLC by National Institute of General Medical Sciences (National Institutes of Health) on September 16, 2022.

How much is award R44GM148138 worth?

$1,730,105 has been obligated on R44GM148138.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login